Cargando…
Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer
Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754394/ https://www.ncbi.nlm.nih.gov/pubmed/32757454 http://dx.doi.org/10.1111/ajco.13380 |
_version_ | 1783626184992489472 |
---|---|
author | Sun, Yuxin Shao, Chi Li, Shan Xu, Yan Xu, Kai Zhang, Ying Huang, Hui Wang, Mengzhao Xu, Zuojun |
author_facet | Sun, Yuxin Shao, Chi Li, Shan Xu, Yan Xu, Kai Zhang, Ying Huang, Hui Wang, Mengzhao Xu, Zuojun |
author_sort | Sun, Yuxin |
collection | PubMed |
description | Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (ILD), and previous radiation therapy for lung cancer might be factors precipitating immune‐related pneumonitis. The incidence of immune‐related pneumonitis is reported to be higher in those treated with PD‐1 inhibitors than in those treated with anti‐PD‐L1 inhibitors. Early detection and diagnosis and appropriate management according to the severity are critical to improving the prognosis. The first‐line physicians, including the primary responsible oncologists, family doctors, emergency physicians and NSCLC patients should be trained to identify and report symptoms of immune‐related pneumonitis as early as possible. Multidisciplinary treatment teams involving clinicians (including ILD specialists and lung cancer specialists), radiologists and pathologists are recommended for the treatment of immune‐related pneumonitis. |
format | Online Article Text |
id | pubmed-7754394 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77543942020-12-23 Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer Sun, Yuxin Shao, Chi Li, Shan Xu, Yan Xu, Kai Zhang, Ying Huang, Hui Wang, Mengzhao Xu, Zuojun Asia Pac J Clin Oncol Reviews Immune‐related pneumonitis is an uncommon but potentially fatal immune‐related adverse event in advanced non–small cell lung cancer (NSCLC) patients during treatment with anti‐programmed cell death 1 (PD‐1) and programmed cell death‐ligand 1 (PD‐L1). Underlying emphysema, interstitial lung disease (ILD), and previous radiation therapy for lung cancer might be factors precipitating immune‐related pneumonitis. The incidence of immune‐related pneumonitis is reported to be higher in those treated with PD‐1 inhibitors than in those treated with anti‐PD‐L1 inhibitors. Early detection and diagnosis and appropriate management according to the severity are critical to improving the prognosis. The first‐line physicians, including the primary responsible oncologists, family doctors, emergency physicians and NSCLC patients should be trained to identify and report symptoms of immune‐related pneumonitis as early as possible. Multidisciplinary treatment teams involving clinicians (including ILD specialists and lung cancer specialists), radiologists and pathologists are recommended for the treatment of immune‐related pneumonitis. John Wiley and Sons Inc. 2020-08-05 2020-12 /pmc/articles/PMC7754394/ /pubmed/32757454 http://dx.doi.org/10.1111/ajco.13380 Text en © 2020 The Authors. Asia‐Pacific Journal of Clinical Oncology published by John Wiley & Sons Australia, Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Reviews Sun, Yuxin Shao, Chi Li, Shan Xu, Yan Xu, Kai Zhang, Ying Huang, Hui Wang, Mengzhao Xu, Zuojun Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title | Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title_full | Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title_fullStr | Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title_full_unstemmed | Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title_short | Programmed cell death 1 (PD‐1)/PD‐ligand 1(PD‐L1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
title_sort | programmed cell death 1 (pd‐1)/pd‐ligand 1(pd‐l1) inhibitors‐related pneumonitis in patients with advanced non–small cell lung cancer |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754394/ https://www.ncbi.nlm.nih.gov/pubmed/32757454 http://dx.doi.org/10.1111/ajco.13380 |
work_keys_str_mv | AT sunyuxin programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT shaochi programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT lishan programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT xuyan programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT xukai programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT zhangying programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT huanghui programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT wangmengzhao programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer AT xuzuojun programmedcelldeath1pd1pdligand1pdl1inhibitorsrelatedpneumonitisinpatientswithadvancednonsmallcelllungcancer |